Last €81.84 EUR
Change Today -0.35 / -0.43%
Volume 4.2K
BIM On Other Exchanges
BIM is not on other exchanges.
As of 5:33 AM 09/23/14 All times are local (Market data is delayed by at least 15 minutes).

biomerieux (BIM) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/30/14 - €83.95
52 Week Low
10/18/13 - €70.65
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOMERIEUX (BIM)

Related News

No related news articles were found.

biomerieux (BIM) Related Businessweek News

No Related Businessweek News Found

biomerieux (BIM) Details

bioMérieux SA designs, develops, manufactures, and markets in vitro diagnostic systems for clinical and industrial applications. The company’s diagnostic systems consist of reagents and consumables used to conduct biological tests, for use in performing screening, diagnostic assistance, prognosis, and treatment monitoring; instruments, platforms, or autoanalyzers used for automated testing at high or low throughputs; software to process analyses and systems to interpret the biological test results; and related services, such as the installation and maintenance of instruments, user training, or the audit of laboratory workflows. It offers diagnostic systems for clinical applications, including the diagnosis of infectious diseases, comprising HIV, tuberculosis, and respiratory diseases, as well as cardiovascular diseases and targeted cancers based on the analysis of biological samples, such as blood, saliva, and urine; and for industrial applications, including the analysis of microbiological manufacturing, such as food, pharmaceuticals, and cosmetics. The company markets and sells its products through a network of distributors to private-sector analysis laboratories, hospital laboratories, blood banks, and physician office laboratories; food, pharmaceutical, and cosmetics industries; and independent quality-control laboratories. It has operations in Europe, the Middle East, Africa, North America, Asia-Pacific, and Latin America. The company was formerly known as B-D Mérieux and changed its name to bioMérieux SA. The company was founded in 1963 and is headquartered in Marcy l’Etoile, France. bioMérieux SA is a subsidiary of Institut Mérieux.

8,535 Employees
Last Reported Date: 09/5/14
Founded in 1963

biomerieux (BIM) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: €544.9K
Compensation as of Fiscal Year 2013.

biomerieux (BIM) Key Developments

bioMérieux Announces Audited Consolidated Earnings Results for the Six Months Ended June 30, 2014; Provides Earnings Guidance for 2014

bioMérieux announced audited consolidated earnings results for the six months ended June 30, 2014. For the period, the company reported sales of €781 million against €754 million a year ago. Operating income before non-recurring items was €79.4 million against €125.1 million a year ago. Operating income was €81 million against €124 million a year ago. Net income attributable to the parent company was €52.3 million or €1.32 per basic and diluted share against €79.7 million or €2.02 per basic and diluted share a year ago. Net cash flow from operations was €107.1 million against €101.7 million a year ago. Purchase of property, plant and equipment was €56.1 million against €59.6 million a year ago. Free cash flow was €69 million against €42 million a year ago. EBITDA (before non-recurring items) was €140.9 million against €169.0 million a year ago. In 2014, the company expects to report sales growth of between 3% and 5% for the year, at constant exchange rates and scope of consolidation. The company demonstrates the resilience of its business model, based on the technological and geographic diversification of its business base. In addition, backed by its sales momentum and the implementation of an operating cost control plan, the company maintains its target to achieve contributive operating income before non-recurring items of between €220 million and €245 million.

bioMérieux SA Presents at Kepler Cheuvreux Autumn Conference 2014, Sep-17-2014

bioMérieux SA Presents at Kepler Cheuvreux Autumn Conference 2014, Sep-17-2014 . Venue: Paris, France. Speakers: Isabelle TONGIO, HEAD of IR.

ATCC and bioMérieux Collaborate to Deliver Accurate Identification of Industrial Microorganisms

ATCC and bioMérieux announced their collaboration to expand and solidify the bioMérieux VITEK(R) MS microbial identification database for the industrial market. Recently, ATCC acquired the bioMérieux VITEK(R) MS system to make this innovative MALDI TOF technology a fundamental component of their authentication and quality control processes. Strengthening the database with additional strains continues to increase the robustness of the VITEK(R) MS micro-organisms library while increasing the size and enhancing the utility for customers as a solid quality assurance tool. The integration of the bioMérieux VITEK(R) MS into ATCC's quality development process will enable ATCC to generate a large pathogen knowledgebase, which will then be incorporated into the VITEK(R) MS database. The newly expanded database will improve the accuracy and range of microbial identification of the bioMérieux VITEK(R) MS.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIM:FP €81.84 EUR -0.35

BIM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $39.97 USD +0.67
Bio-Rad Laboratories Inc $117.73 USD +0.21
Hologic Inc $24.79 USD +0.65
QIAGEN NV €18.49 EUR -0.101
Siemens Ltd 885.55 INR -2.10
View Industry Companies

Industry Analysis


Industry Average

Valuation BIM Industry Range
Price/Earnings 22.3x
Price/Sales 1.9x
Price/Book 2.4x
Price/Cash Flow 22.3x
TEV/Sales 1.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOMERIEUX, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at